TY - JOUR
T1 - New insights for vaccine development against Clostridium difficile infections
AU - Pizarro-Guajardo, Marjorie
AU - Chamorro-Veloso, Nayaret
AU - Vidal, Roberto Mauricio
AU - Paredes-Sabja, Daniel
N1 - Funding Information:
This work was supported by grants from Fondo Nacional de Ciencia y Tecnología de Chile (FONDECYT Grant 1151025 ) and by Millennium Science Initiative of the Ministry of Economy , Development and Tourism to D.P-S. Support was also provided by a grant from Fondo de Fomento al Desarrollo Científico y Tecnológico (FONDEF) ID18|10230 to M.P-G and D.P-S.
Funding Information:
This work was supported by grants from Fondo Nacional de Ciencia y Tecnolog?a de Chile (FONDECYT Grant 1151025) and by Millennium Science Initiative of the Ministry of Economy, Development and Tourism to D.P-S. Support was also provided by a grant from Fondo de Fomento al Desarrollo Cient?fico y Tecnol?gico (FONDEF) ID18|10230 to M.P-G and D.P-S.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Increased antibiotic usage is the main risk factor for gut microbiota dysbiosis. In dysbiosis, there is an increased susceptibility to intestinal pathogens, such as Clostridium difficile infection, the leading cause of hospital-acquired infection worldwide. High-spectrum antibiotics, such as vancomycin or metronidazole, also increases the risk of developing CDI symptoms after the treatment. An impaired immune response could also be responsible for the high incidence of recurrence of CDI (R-CDI), suggesting that immune system stimulation could help eradicate the infection in patients suffering multiple episodes in CDI or prevent the infective course. Here, we discuss novel immunotherapeutic approaches that aid the immune system to target C. difficile and how these can be improved.
AB - Increased antibiotic usage is the main risk factor for gut microbiota dysbiosis. In dysbiosis, there is an increased susceptibility to intestinal pathogens, such as Clostridium difficile infection, the leading cause of hospital-acquired infection worldwide. High-spectrum antibiotics, such as vancomycin or metronidazole, also increases the risk of developing CDI symptoms after the treatment. An impaired immune response could also be responsible for the high incidence of recurrence of CDI (R-CDI), suggesting that immune system stimulation could help eradicate the infection in patients suffering multiple episodes in CDI or prevent the infective course. Here, we discuss novel immunotherapeutic approaches that aid the immune system to target C. difficile and how these can be improved.
KW - BclA
KW - CdeC
KW - CdeM
KW - Clostridium difficile spores
KW - Exosporium
KW - Novel epitopes
KW - Spore coat
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85068266912&partnerID=8YFLogxK
U2 - 10.1016/j.anaerobe.2019.04.009
DO - 10.1016/j.anaerobe.2019.04.009
M3 - Review article
C2 - 31034928
AN - SCOPUS:85068266912
SN - 1075-9964
VL - 58
SP - 73
EP - 79
JO - Anaerobe
JF - Anaerobe
ER -
